Top Markets
#1 Black Phoenix Black Phoenix +199.74%
#2 Islamic Coin Islamic Coin +158.05%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +56.25%
#5 Akedo Akedo +41.31%
#6 BasedHype BasedHype +32.44%
#7 Acurast Acurast +26.87%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.07%
#9 Cryptopia Cryptopia +22.04%
#10 Quantum Resistant Ledger Quantum Resistant Ledger +17.37%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Timber Pharmaceuticals, Inc. Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc.

TMBR
Classifica tra le azioni #42059
Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials. It is designed to address moderate to severe forms of Congenital Ichthyosis (CI), a group of uncommon genetic disorders affecting skin keratinization. TMB-002, a proprietary topical rapamycin, currently undergoing Phase 2b clinical trials. This therapy targets facial angiofibroma associated with Tuberous Sclerosis Complex, a complex genetic disorder characterized by the growth of benign tumors in multiple organs. TMB-003, a unique Sitaxsentan formulation functioning as a selective endothelin-A receptor antagonist, which is in preclinical development for various sclerotic skin diseases. Additionally, through a licensing agreement with AFT Pharmaceuticals Limited, Timber Pharmaceuticals is advancing two topical minocycline therapies: BPX-01, now in Phase 3 development for treating inflammatory lesions of acne vulgaris. BPX-04, which is prepared for Phase 3 trials, targeting papulopustular rosacea. Founded in 2019, Timber Pharmaceuticals is headquartered in Basking Ridge, New Jersey.
Prezzo delle azioni
$0.0101
Ultima sincronizzazione: 2023-12-26
Capitalizzazione di mercato
$5.32K
Variazione (1 giorno)
741.67%
Variazione (1 anno)
0.00%
Paese
US
Scambia Timber Pharmaceuticals, Inc. (TMBR)

Categoria

Healthcare
Rapporto P/B per Timber Pharmaceuticals, Inc. (TMBR)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Timber Pharmaceuticals, Inc., il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per Timber Pharmaceuticals, Inc. da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.2613 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.3483 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.634 -
BE